from Reuters: Business News https://ift.tt/2V1ADPP
Friday, March 29, 2019
AstraZeneca could pay Daiichi Sankyo up to $6.9 billion in cancer drug deal
AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi's cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner.
from Reuters: Business News https://ift.tt/2V1ADPP
from Reuters: Business News https://ift.tt/2V1ADPP
Related Posts:
ECB's Enria says merged banking giant must have extra capital, be 'resolvable'- Levi Strauss Heads Back to Public Markets Amid IPO Boom
- Volkswagen, Northvolt to join forces for battery research
- What the WHO gets wrong about video games and culture
- Solar and wind firms call the 'Green New Deal’ too extreme
0 comments:
Post a Comment